Published online before print September 2, 2004, doi: 10.1161/01.RES.0000143898.67182.4c
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Integrative Physiology |
Transgenic Expression of Bcl-2 Modulates Energy Metabolism, Prevents Cytosolic Acidification During Ischemia, and Reduces Ischemia/Reperfusion Injury
From the Laboratory of Signal Transduction (K.I., E.M.), National Institutes of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC; Department of Pathology (C.S.), Duke University Medical Center, Durham, NC; and the Department of Medicine (M.D.S.), Molecular and Cellular Biology, and Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Tex.
Correspondence to Elizabeth Murphy, Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709. E-mail murphy1{at}niehs.nih.gov
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The antiapoptotic protein Bcl-2 is targeted to the mitochondria, but it is uncertain whether Bcl-2 affects only myocyte survival after ischemia, or whether it also affects metabolic functions of mitochondria during ischemia. Hearts from mice overexpressing human Bcl-2 and from their wild-type littermates (WT) were subjected to 24 minutes of global ischemia followed by reperfusion. During ischemia, the decrease in pHi and the initial rate of decline in ATP were significantly reduced in Bcl-2 hearts compared with WT hearts (P<0.05). The reduced acidification during ischemia was dependent on the activity of mitochondrial F1F0-ATPase. In the presence of oligomycin (Oligo), an F1F0-ATPase inhibitor, the decrease in pHi was attenuated in WT hearts, but in Bcl-2 hearts, Oligo had no additional effect on pHi during ischemia. Likewise, addition of Oligo to WT hearts slowed the rate of decline in ATP during ischemia to a level similar to that observed in Bcl-2 hearts, but addition of Oligo had no significant effect on the rate of decline in ATP in Bcl-2 hearts during ischemia. These data are consistent with Bcl-2–mediated inhibition of consumption of glycolytic ATP. Furthermore, mitochondria from Bcl-2 hearts have a reduced rate of consumption of ATP on uncoupler addition. This could be accomplished by limiting ATP entry into the mitochondria through the voltage-dependent anion channel, and/or the adenine nucleotide transporter, or by direct inhibition of the F1F0-ATPase. Immunoprecipitation showed greater interaction between Bcl-2 and voltage-dependent anion channel during ischemia. These data indicate that Bcl-2 modulation of metabolism contributes to cardioprotection.
Key Words: transgenic models • magnetic resonance spectroscopy • mitochondria • reperfusion injury
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Bcl-2 is an antiapoptotic protein that was originally found to be overexpressed in B-cell lymphoma because of a chromosomal translocation.1 Recent studies suggest that Bcl-2 may have a more general role in regulating mitochondrial metabolism and function,2,3 and that its protective effect may not be limited to an antiapoptotic role. Bcl-2 is the founding member of a family of proteins involved in apoptosis, which includes antiapoptotic members such as Bcl-2 and Bcl-xL4,5 and proapoptotic members such as BAX, BAK, and Bid.4,6,7 Emerging data suggest that proapoptotic family members such as BAX enter the outer mitochondrial membrane and form a large conductance channel that allows release of cytochrome c.8,9 The precise mechanism by which BAX mediates release of cytochrome c is not well understood, but has been suggested to involve channels formed by BAX or by BAX in association with other mitochondrial proteins such as the voltage-dependent anion channel (VDAC), or the mitochondrial permeability transition pore (MPTP), which is suggested to be composed of the adenine nucleotide transporter (ANT), VDAC, and cyclophilin.6,10,11 However, recent data have questioned the role of ANT in the MPTP.12 It has been suggested that antiapoptotic family members such as Bcl-2 oppose release of cytochrome c either by binding and sequestering proapoptotic members,4 or by binding to proteins such as VDAC and blocking the formation or opening of a cytochrome c release pathway.5,10,11 Bcl-2 is localized to the outer mitochondrial membrane and Bcl-2 family proteins have been reported to interact with VDAC.5,7 There is controversy as to whether Bcl-2 binding to VDAC promotes the opening or closing of VDAC.10,13 Thompson and coworkers8,10 report that Bcl-2 maintains VDAC in an open state, whereas Shimizu et al5,11,13 report that Bcl-2 promotes VDAC closure.
VDAC, the most abundant protein in the outer mitochondrial membrane, allows transport of adenine nucleotides, metabolites, and ions across the outer mitochondrial membrane. In vitro, VDAC has been shown to decrease conductance when either a positive or negative potential is applied.14 VDAC in concert with ANT controls transport of adenine nucleotides in and out of the mitochondria, a function that is extremely important for a cardiomyocyte, which is dependent on mitochondrial oxidative phosphorylation and where mitochondria compose >30% of cell volume. Mitochondrial generation of ATP occurs via the F1F0-ATPase, which uses the proton gradient generated by electron transport to provide the driving force for converting ADP to ATP. Cell energetics depends on the appropriate transport of ADP into the mitochondria and the transport of ATP to the cytosol. Thus, Bcl-2–mediated alteration in adenine nucleotide transport could have important implications for cardiac energetics. During ischemia, when lack of oxygen inhibits mitochondrial electron transport and mitochondrial generation of ATP, the F1F0-ATP can run in reverse and consume glycolytically generated ATP.15–19 In fact, many cells contain a natural inhibitor of the F1F0-ATPase, which binds the F1F0-ATPase during ischemia to inhibit breakdown of glycolytic ATP.20 There are also data showing that ischemia and anoxia lead to a preferential decrease in cytosolic versus mitochondrial ATP,21,22 suggesting that cells may regulate mitochondrial ADP/ATP exchange during ischemia.
The aim of this study was to obtain insights into the mechanism by which cardiac-specific overexpression of Bcl-2 suppresses cell death as well as potential mechanisms by which Bcl-2 might modulate cellular metabolism. We found that Bcl-2 overexpression, in addition to reducing ischemia/reperfusion injury,23–25 also reduced the rate of decline in ATP during ischemia and reduced ischemic acidification; these data are consistent with Bcl-2–mediated inhibition of consumption of glycolytically generated ATP. Consistent with this hypothesis, we further showed that the reduction in acidification and the rate of decline in ATP during ischemia was dependent on the activity of the mitochondrial F1F0-ATPase. Bcl-2–mediated inhibition of glycolytically generated ATP could be accomplished by limiting ATP entry into the mitochondria through VDAC or ANT, or by direct inhibition of the F1F0-ATPase. Consistent with this hypothesis, we find that Bcl-2 overexpression reduces the rate of mitochondrial ATP consumption under conditions in which ATP hydrolysis is stimulated.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Animals
All animals (Baylor College of Medicine, Houston, Tex) were treated in accordance with National Institutes of Health guidelines. Fifty-six mice of either sex were used. We originally analyzed males and females separately but because there were no significant differences between males and females, the data from both sexes were combined. Two experimental groups were studied: cardiac-specific expression of human Bcl-2-
MHC (Bcl-2) and age-matched wild-type littermates (WT).
Heart Perfusion and Protocols
Mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (80 mg/kg body weight), and hearts were excised and perfused as described previously.26 Briefly, hearts were cannulated and perfused in the Langendorff mode, at a constant pressure of 100 cmH2O, with Krebs-Henseleit buffer containing (in mmol/L) NaCl 120, KCl 5.9, MgSO4 1.2, CaCl2 1.75, NaHCO3 25, and glucose 11. The buffer was aerated with 95% O2 and 5% CO2, to give a pH of 7.4 at 37°C.
All hearts were perfused for a stabilization period of 20 to 30 minutes. Hearts then were subjected to a 24-minute period of ischemia at 37°C and 2 hours of reperfusion. Left ventricular developed pressure (LVDP), ±dP/dt, and heart rate were continuously monitored via a water-filled latex balloon inserted into the left ventricle. Recovery of contractile function was assessed by measurement of LVDP and rate-pressure product (RPP) during reperfusion and was expressed as a percentage of preischemic LVDP or RPP. Two baseline (preischemic) 31P-NMR spectra were obtained. During 24 minutes of ischemia, we acquired five NMR spectra. Spectra were obtained every 5 minutes during the 2 hours of reperfusion. In some hearts, oligomycin (
3 µg/mL, 0.3% DMSO) was administered 4 minutes before ischemia to estimate the role of F1F0-ATPase during ischemia. After the experiment, hearts were weighed, and used for TTC staining, TUNEL staining, or Western blot analysis.
Nuclear Magnetic Resonance Spectroscopy
Relative changes in the concentration of high-energy phosphate metabolites were measured during the ischemia/reperfusion protocol by acquiring consecutive 5-minute 31P-NMR spectra using a Varian 500 MHz spectrometer with an 11.7-Tesla superconducting magnet at the 31P resonance frequency of 202.47 MHz. Intracellular pH was estimated from the chemical shift between inorganic phosphate (Pi) and phosphocreatine (PCr) as described previously.26 In some hearts, extracellular pH was determined by the shift difference between phenylphosphonic acid (PPA) and PCr.27 An expanded Materials and Methods section can be found in the online data supplement available at http://circres.ahajournals.org.
Measurement of Infarct Size and Apoptosis
At the end of 2 hours of reperfusion, the hearts were cut into thin cross-sectional slices and then were incubated in a 0.08% solution of 2,3,5-triphenyltetrazolium chloride (TTC) dissolved in Krebs-Henseleit buffer at 37°C for 30 minutes. The slices were then fixed in formalin. The area of necrosis was quantitated by measuring the stained area (live tissue) versus the unstained area (necrotic) using a digital camera mounted on an Olympus stereomicroscope. To measure apoptotic cell death, immunoperoxidase TUNEL staining was performed. The sections were counterstained with hematoxylin to identify cardiac myocytes and TUNEL-positive cardiac myocyte nuclei were counted in 10 randomly selected fields by a blinded observer.
Heart and Mitochondria Preparation for Western Blot Analysis
Whole cell samples, the mitochondria-enriched fraction, or cytosolic fraction were prepared by differential centrifugation from the frozen heart. Details can be found in the online data supplement. For determination of Bcl-2, VDAC, Bak, Bcl-xL, and apoptosis-inducing factor (AIF), 50 µg of homogenate protein was separated by electrophoresis. After transfer to a nitrocellulose membrane, the membrane was incubated with anti–Bcl-2 antibody (Transduction Laboratories), anti-VDAC antibody (Calbiochem), anti-Bak antibody (Upstate Biotechnology), anti–Bcl-xL antibody (Cell Signaling), or anti-AIF antibody (BD PharMingen) in TBS-T with 5% BSA/milk at 4°C overnight. Membranes were incubated with the secondary antibody, appropriate horseradish peroxidase–conjugated IgG in TBS-T with 5% dry fat milk for 1 hour at room temperature. Immunoreactive protein was visualized using an enhanced chemiluminescence analysis kit (Amersham Pharmacia Biotech Inc).
Immunoprecipitation Study
The mitochondrial fraction (500 µg) was incubated with 1 µg of VDAC antibody or Bcl-2 (Santa Cruz) in a buffer containing (in mmol/L) NaCl 150, HEPES 20 (pH 7.4), EDTA 10, Na3VO4 1, 0.1% Nonidet-P40, and protease inhibitors for 2 hours at 4°C. Protein G agarose (30 µL) was added and was incubated at 4°C overnight. The beads were washed four times and suspended with sample buffer, boiled, centrifuged, and the supernatants were subjected to immunoblotting [Bcl-2 mouse monoclonal (Transduction Laboratory) or VDAC mouse monoclonal (Calbiochem)].
Isolated Mitochondria Study
Freshly isolated mitochondria (25 mg/mL) were prepared from the ventricles of two hearts by differential centrifugation. Measurement of mitochondrial respiration was performed at 25°C in a chamber (600 µL) connected with a Clark-type O2 electrode (Instech) and O2 monitor (Model 5300, YSI, Inc). The mitochondria were incubated in a chamber containing respiration buffer (in mmol/L) KCl 120, MOPS 5, EGTA 1, KH2PO4 5, and 0.2% BSA. After addition of glutamate/malate (10 mmol/L), state 3 respiration was measured by addition of ADP (0.125 to 0.5 mmol/L). On depletion of ADP, state 4 respiration was determined. Uncoupled respiration was determined by adding an uncoupler, 2,4,-dinitrophenol (DNP, 50 µmol/L). The maximum ADP-stimulated respiration (Vmax) was estimated from a linear regression of double-reciprocal plots.
ATP uptake into mitochondria and hydrolysis was measured by adding ATP (875 µmol/L) to mitochondria followed by addition of DNP (50 µmol/L). After the indicated time, oligomycin (1 µg/mL) was added to block ATP hydrolysis and the supernatant was obtained by brief centrifugation. ATP remaining in the supernatant was measured. To confirm that ATP hydrolysis was dependent on ATP transport into the mitochondria, an ANT blocker, atractyloside (ATR, 50 µmol/L), or a VDAC inhibitor, 4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS, 100 µmol/L), were added before DNP. To examine the direct effect of Bcl-2 on mitochondrial ATP uptake and hydrolysis, we incubated recombinant Bcl-2 protein (rBcl-2, Full length, HA-tag-inserted form, Amprox, USA) with isolated mitochondria for 5 minutes at room temperature before the experiments.
Statistical Analysis
Results are expressed as mean±SEM. For comparison between 2 groups, significance was determined by Student t test. For comparison among 4 groups, ANOVA and a Fisher post hoc test analysis was used. A value of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Basal Contractile Function and Bcl-2 Expression
The Table shows that there were no differences in the baseline hemodynamic parameters between Bcl-2 and WT hearts. Table 1 also shows that the heart/body weight ratio was not significantly different between Bcl-2 and WT mice ([4.0±0.1]x10–3 in Bcl-2 versus [4.0±0.1]x10–3 in WT; P>0.05). Western blot analysis confirmed that the expression of Bcl-2 protein was higher in Bcl-2 hearts than in WT hearts (Figure 1A).
|
|
Bcl-2 Overexpression Reduces Infarct Size and Improves Postischemic Function
As shown in Figure 1B, infarct size, measured with TTC staining, was significantly smaller in Bcl-2 hearts (18±3%) than in WT hearts (38±5%, P<0.05). This 50% reduction in infarct size in the Langendorff model was similar to that observed in these Bcl-2 overexpressing hearts using an in vivo model of coronary occlusion and reperfusion (Schneider et al, unpublished data, 2004). We also confirmed that the TUNEL-positive apoptotic cardiac myocyte death was reduced by 73% in our model (4.3±1.7% myocytes showed apoptosis in WT versus 1.2±0.9% in Bcl-2). Figure 1C shows that after 2 hours of reperfusion, Bcl-2 transgenic hearts had significantly improved postischemic contractile function as measured by recovery of rate pressure product (RPP; left ventricular developed pressure (LVDP)xheart rate, expressed as a % initial RPP, 55±4% in Bcl-2 hearts versus 27±3% in WT hearts; P<0.05), or recovery of LVDP (78.9±7.8 cmH2O in Bcl-2 hearts versus 38.0±3.1 cmH2O in WT hearts; P<0.05). On reperfusion, the rate of contraction (+dP/dt) and rate of relaxation (–dP/dt) were also significantly better in Bcl-2 hearts compared with WT hearts (3676±363 cmH2O/s, –2392±334 in Bcl-2 versus 2112±295, –1193±203 in WT; P<0.05). Figure 1D shows that release of the proapoptotic factor, AIF, from the mitochondria to the cytosol was attenuated in Bcl-2 hearts compared with WT hearts. AIF release from the mitochondria has been used as a marker for apoptosis. AIF is released from the mitochondria to the cytosol and nucleus; it has been reported to cause chromatin condensation in the nucleus.28 These data indicate that Bcl-2 overexpression inhibits both necrotic and apoptotic death pathways during ischemia/reperfusion.
High-Energy Phosphate Metabolites and pHi
Figure 2 shows the changes in [ATP], [PCr], and pHi at baseline, during ischemia and during reperfusion in WT and Bcl-2 hearts. At baseline, there were no significant differences in pHi between WT and Bcl-2 hearts (WT, 7.28±0.04 versus Bcl-2, 7.27±0.01; P>0.05). During ischemia, the decrease in pHi was significantly reduced in Bcl-2 hearts (6.49±0.06) compared with WT hearts (6.26±0.07; P<0.05). During reperfusion, pHi was similar in Bcl-2 and WT hearts. At baseline, there were no significant differences in creatine phosphate (PCr) or ATP content between Bcl-2 and WT hearts. At the end of ischemia there were no significant differences in ATP between the groups, although the rate of ATP decline during the first 10 minutes of ischemia was slower in the Bcl-2 hearts than in WT hearts. During reperfusion, ATP recovered similarly in both Bcl-2 hearts and WT hearts. PCr declined to similar levels in both WT and Bcl-2 hearts during ischemia. After 2 hours of reperfusion, the postischemic recovery of PCr was significantly better in Bcl-2 hearts (85±5% of preischemic level) than in WT hearts (60±4%; P<0.05), consistent with smaller infarcts in the Bcl-2 hearts and therefore better retention of creatine. These results indicate that Bcl-2 overexpression reduced cytosolic acidification during ischemia, slowed the rate of decline in ATP, and allowed improved PCr recovery during reperfusion.
|
Effect of F1F0-ATPase Inhibition During Ischemia
To explore the mechanism responsible for the reduced acidification observed during ischemia in Bcl-2 hearts, we performed a series of studies to investigate the role of the F1F0-ATPase. During global ischemia, ATP is generated by anaerobic glycolysis and if this glycolytic ATP is consumed by the F1F0-ATPase, this would accelerate the decline in ATP content and increase acidification during ischemia. To test whether the F1F0-ATPase is involved in the reduced acidification observed in Bcl-2 hearts, we treated hearts with oligomycin, a specific inhibitor of the F1F0-ATPase. Oligomycin has been reported to decrease acidification during ischemia because it blocks the breakdown of glycolytic ATP.15 We reasoned that if the effects of Bcl-2 were mediated by a pathway that included the F1F0-ATPase, then the reduced acidification observed with Bcl-2 and oligomycin should not be additive. We selected an oligomycin concentration that was in the lower range of those previously used16 (3 µmol/L), and it was administered for 4 minutes before ischemia. As shown in Figure 3, consistent with the data in Figure 2, we found reduced acidification during ischemia in untreated Bcl-2 hearts. We also found that F1F0-ATPase inhibition by oligomycin significantly reduced cytosolic acidification in WT hearts to a level similar to that observed in Bcl-2 transgenic hearts. Figure 3 further shows that in Bcl-2 transgenic hearts oligomycin had no additional effect on pHi during ischemia. Thus, there was no significant difference in pHi between WT and Bcl-2 hearts treated with oligomycin (Figure 3, P>0.05). To exclude the possibility that the reduced acidification in Bcl-2 hearts was attributable to the enhanced proton efflux across the plasma membrane, we also measured pHe during ischemia by adding phenylphosphonic acid to the perfusate. If the reduced pH in Bcl-2 hearts was attributable to enhanced efflux, we would expect a lower pHe in Bcl-2 hearts; instead we found that pHe at the end of ischemia was slightly higher in Bcl-2 hearts (6.4±0.1) than in WT hearts (6.2±0.1). These data are entirely consistent with our previous findings that preconditioning results in a parallel attenuation of the decrease in both intracellular and extracellular pH during ischemia.27 These data confirm that the reduced acidification in Bcl-2 hearts is not attributable to enhanced proton efflux from the cell, and are consistent with a role for the F1F0-ATPase in the reduced cytosolic acidification during ischemia in Bcl-2 hearts.
|
P<0.05 versus untreated Bcl-2 hearts.As discussed, inhibition of the F1F0-ATPase would be expected to reduce the rate of decline in ATP during ischemia. We therefore measured the initial rate of decline in ATP during the first 10 minutes of ischemia. As shown in Figure 4, the rate of decline in ATP was slower in Bcl-2 hearts than in WT hearts (P<0.05). Oligomycin reduced the rate of decrease in ATP in WT hearts but addition of oligomycin had no additional effect in Bcl-2 hearts, suggesting that Bcl-2 and oligomycin are affecting a common pathway. Because oligomycin cannot be readily removed from the perfused heart, it is not possible to measure the recovery of ATP or LVDP during reperfusion.
|
Interaction of Bcl-2 With VDAC During Ischemia
The oligomycin data suggest that Bcl-2 can reduce consumption of glycolytic ATP via the reverse mode of the F1F0-ATPase. Bcl-2 could accomplish this by limiting entry of cytosolic ATP into the mitochondria (through VDAC or ANT) or by direct inhibition of the F1F0-ATPase. Because Bcl-2 and VDAC are both located on the outer mitochondrial membrane and it has previously been demonstrated that Bcl-xL interacts with VDAC,5 we examined whether an interaction between Bcl-2 and VDAC occurs in heart. Western blot data show that a similar amount of VDAC was present in Bcl-2 and WT mitochondria (Figure 5A). There was also no apparent difference in Bak or Bcl-xL levels between WT and Bcl-2 mitochondria. As shown in Figure 5B, immunoprecipitation with VDAC showed a significant association with Bcl-2 in the Bcl-2 hearts. Furthermore, immunoprecipitation with Bcl-2 confirms an association with VDAC. As shown in Figure 5C, we found increased binding of Bcl-2 to VDAC before and during ischemia in Bcl-2 and WT hearts (P<0.05). We also found that ischemia increased the binding of Bcl-2 to VDAC compared with preischemia in both WT and Bcl-2 hearts, but the increase was only significant in the Bcl-2 hearts (P<0.05).
|
ATP/ADP Flux in Bcl-2 Overexpressed Mitochondria
Figure 6A shows reciprocal plots of ADP-stimulated (state 3) oxygen consumption rates under normal conditions, indicating no inhibition of ADP flux under normal conditions between WT and Bcl-2 mitochondria (Vmax, 145±13 [nmol O/mgxmin] in WT, 124±6 in Bcl-2; P>0.05). Figure 6B showed that under normoxic condition, Bcl-2 does not limit ADP flux into mitochondria. Interestingly, with addition of the mitochondrial uncoupler DNP, the rate of ATP consumption was significantly less in mitochondria isolated from hearts that overexpress Bcl-2 than in WT mitochondria (Figures 6C and 7A). This is consistent with the reduced cytosolic ATP depletion during ischemia observed in Bcl-2 hearts. Mitochondrial ATP breakdown was completely blocked by inhibition of ATP transport using an inhibitor of ANT, ATR or an inhibitor of VDAC, DIDS (Figure 7A). We also examined whether addition of recombinant Bcl-2 (rBcl-2) to isolated mitochondria would alter the rate of ATP uptake and consumption. As shown in Figure 7B, rBcl-2 bound to isolated mitochondria and remained following washing. Furthermore, mitochondria containing rBcl-2 protein showed the reduced ATP uptake and hydrolysis (Figure 7B), providing additional support for the hypothesis.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this study, we found that hearts overexpressing Bcl-2 showed improved postischemic recovery of left ventricular developed pressure, reduced infarct size, and improved postischemic recovery of phosphocreatine. These data are consistent with previous studies showing that cardiac-specific overexpression of Bcl-2 reduced ischemia/reperfusion injury.23,24 In addition, this study provides new insights into the mechanism by which Bcl-2 mediates cardioprotection. We show that hearts overexpressing Bcl-2 have a slower rate of decline in ATP during ischemia and reduced ischemic acidification, and these were dependent on the activity of the mitochondrial F1F0-ATPase, suggesting that oligomycin and Bcl-2 affect a common pathway.7,29 These data add to the emerging concept that Bcl-2 modulates mitochondrial physiology and function.
With a slower rate of decline in ATP, during early ischemia there would be more ATP and therefore less ionic alterations and less activation of degradative enzymes. The reduced acidification has been shown to be beneficial because there is less stimulation of Na+/H+ exchange, and therefore less of a rise in Na+, resulting in less Na+/Ca2+ exchange and less of a rise in Ca2+.30 The reduction in Ca2+ during ischemia has been shown in many studies to reduce ischemic injury. Furthermore, if lethal cell injury is related to the time interval after ATP reaches a critically low value, then slowing the rate of ATP depletion would be protective.
There are considerable data in the literature suggesting that there is a marked decline in mitochondrial membrane potential during ischemia or metabolic inhibition of sufficient duration to cause significant depletion of ATP.17,18,31 Furthermore, the decrease in mitochondrial membrane potential during simulated ischemia is faster and more complete with addition of oligomycin.18,19 These data are interpreted as showing that glycolytic ATP is used to maintain the mitochondrial membrane potential during ischemia via reverse mode F1F0-ATPase activity.19 Furthermore, during ischemia, the F1F0-ATPase consumes glycolytic ATP, thus contributing to depletion of ATP and cytosolic acidification caused by increased generation of lactate.15,16 We find that Bcl-2 slows the rate of decline in ATP and reduces ischemic acidification during ischemia, consistent with Bcl-2 induced inhibition of consumption of glycolytically generated ATP. This could be accomplished by Bcl-2 induced closure of VDAC, closure of ANT, or inhibition of F1F0-ATPase. Consistent with this hypothesis, we find that oligomycin and Bcl-2 have similar effects on the rate of decline in ATP and acidification during ischemia and that the effects of oligomycin and Bcl-2 are not additive. In addition, compared with WT hearts, we find a significantly reduced rate of ATP consumption after addition of uncoupler to mitochondria isolated from Bcl-2 hearts or when recombinant Bcl-2 is incorporated into isolated WT mitochondria. The location of Bcl-2 in the outer mitochondrial membrane favors interaction between Bcl-2 and VDAC.5 In further support of this hypothesis, we find greater association of Bcl-2 and VDAC in Bcl-2 hearts during ischemia. However, the precise mechanism by which Bcl-2 reduces consumption of glycolytically generated ATP will require further study.
There are conflicting data regarding the relationship of Bcl-2 to VDAC and ATP/ADP transport across the mitochondria. Thompson and coworkers report that Bcl-2 reduced the rate of decline in ATP associated with growth factor withdrawal induced apoptosis;32 these observations were attributed to Bcl-2 maintaining VDAC in an open conformation thereby allowing ATP/ADP exchange across the mitochondrial membranes. It was hypothesized that growth factor withdrawal–induced apoptosis leads to closure of VDAC, which results in decreased cytosolic ATP because of inhibition of mitochondrial ATP/ADP exchange. Under these conditions, oxygen is present and mitochondrial ATP generation can be a source of cytosolic ATP, and thus oligomycin would have a similar effect to VDAC inhibition and would inhibit mitochondrial ATP generation. In contrast, Shimizu et al,5 using reconstituted liposomes and radiolabeled sucrose uptake as a measure of VDAC activity, reported that BAX enhanced VDAC opening, whereas Bcl-2 promoted VDAC closure. Additional studies by this group showed that BAX-induced apoptosis was blocked by injection of antibodies that inhibited the opening of VDAC.11
Mitochondria regulate tightly the transport of ATP and ADP. If ATP generated in the mitochondria cannot get to the cytosol because of the inhibition of VDAC under normal aerobic conditions, cell function will be impaired. Alternatively, if oxygen is limiting, it would be advantageous to block mitochondrial consumption of glycolytically generated ATP. Bcl-2 mediated inhibition of adenine nucleotide transport or inhibition of the F1F0-ATPase would only be protective during ischemia. Under normal aerobic conditions, inhibition of these processes would impair the transport of ATP and/or the generation of ATP by oxidative phosphorylation. Interestingly, it has been suggested that mitochondrial ATP/ADP transport is inhibited during ischemia.20,33 Our data indicate that overexpression of Bcl-2 does not block adenine nucleotide transport into mitochondria under normal aerobic conditions; however, on addition of an uncoupler, mitochondria from Bcl-2 hearts exhibit a reduced rate of ATP hydrolysis, consistent with reduced entry of ATP into the mitochondria. Bcl-2 insertion into the mitochondrial membrane is enhanced by decreased pH,5 which occurs during ischemia. The finding that acidic conditions are required to induce cell death by a Bcl-2 family protein-dependent pathway34 is consistent with a functional role of Bcl-2 during ischemia.
In summary, we find that Bcl-2, in addition to reducing ischemic injury, reduces acidification and the rate of decline in ATP during ischemia by reducing the consumption of glycolytically generated ATP. This may be involved as an early step in Bcl-2–induced cardioprotection.
|
Acknowledgments |
|---|
This work was supported in part by NIH grants (to M.D.S. and C.S.). K.I. and E.M. were supported by the NIEHS intramural program. We thank Dr Robert E. London for use of the NMR facilities at the NIEHS. We also thank Scott A. Gabel, Diane Magnusom, John G. Petranka, and Dr Gary Wright for their assistance.
|
Footnotes |
|---|
Original received July 30, 2003; resubmission received April 26, 2004; revised resubmission received July 26, 2004; accepted August 19, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A. 1985; 82: 7439–7443.
2. Garland JM, Halestrap A. Energy metabolism during apoptosis. Bcl-2 promotes survival in hematopoietic cells induced to apoptose by growth factor withdrawal by stabilizing a form of metabolic arrest. J Biol Chem. 1997; 272: 4680–4688.
3. Manfredi G, Kwong JQ, Oca-Cossio JA, Woischnik M, Gajewski CD, Martushova K, D’Aurelio M, Friedlich AL, Moraes CT. BCL-2 improves oxidative phosphorylation and modulates adenine nucleotide Translocation in mitochondria of cells harboring mutant mtDNA. J Biol Chem. 2003; 278: 5639–5645.
4. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001; 8: 705–711.[CrossRef][Medline] [Order article via Infotrieve]
5. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999; 399: 483–487.[CrossRef][Medline] [Order article via Infotrieve]
6. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998; 95: 4997–5002.
7. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y. Bax interacts with the permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A. 1998; 95: 14681–14686.
8. Vander Heiden MG, Thompson CB. Bcl-2 proteins: regulators of the apoptosis or of mitochondrial homeostasis? Nat Cell Biol. 1999; 1: E209–E216.[CrossRef][Medline] [Order article via Infotrieve]
9. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003; 112: 481–490.[CrossRef][Medline] [Order article via Infotrieve]
10. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000; 7: 1182–1191.[CrossRef][Medline] [Order article via Infotrieve]
11. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem. 2000; 275: 12321–12325.
12. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 2004; 427: 461–465.[CrossRef][Medline] [Order article via Infotrieve]
13. Tsujimoto Y, Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 2000; 7: 1174–1181.[CrossRef][Medline] [Order article via Infotrieve]
14. Wunder UR, Colombini M. Patch clamping VDAC in liposomes containing whole mitochondrial membranes. J Membr Biol. 1991; 123: 83–91.[CrossRef][Medline] [Order article via Infotrieve]
15. Rouslin W, Erickson JL, Solaro RJ. Effects of oligomycin and acidosis on rates of ATP depletion in ischemic heart muscle. Am J Physiol. 1986; 250: H503–H508.[Medline] [Order article via Infotrieve]
16. Vuorinen K, Ylitalo K, Peuhkurinen K, Raatikainen P, Ala-Rami A, Hassinen IE. Mechanisms of ischemic preconditioning in rat myocardium. Roles of adenosine, cellular energy state, and mitochondrial F1F0-ATPase. Circulation. 1995; 91: 2810–2818.
17. Di Lisa F, Blank PS, Colonna R, Gambassi G, Silverman HS, Stern MD, Hansford RG. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J Physiol. 1995; 486: 1–13.
18. Leyssens A, Nowicky AV, Patterson L, Crompton M, Duchen MR. The relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i and [Ca2+]i studied in isolated rat cardiomyocytes. J Physiol. 1996; 496: 111–128.
19. Di Lisa F, Menabo R, Canton M, Petronilli V. The role of mitochondria in the salvage and the injury of the ischemic myocardium. Biochim Biophys Acta. 1998; 1366: 69–78.[Medline] [Order article via Infotrieve]
20. Rouslin W. Regulation of the mitochondrial ATPase in situ in cardiac muscle: role of the inhibitor subunit. J Bioenerg Biomembr. 1991; 23: 873–888.[CrossRef][Medline] [Order article via Infotrieve]
21. Aw TY, Andersson BS, Jones DP. Mitochondrial transmembrane ion distribution during anoxia. Am J Physiol. 1987; 252: C356–C361.[Medline] [Order article via Infotrieve]
22. Murphy E, Gabel SA, Funk A, London RE. NMR observability of ATP: preferential depletion of cytosolic ATP during ischemia in perfused rat liver. Biochemistry. 1988; 27: 526–528.[CrossRef][Medline] [Order article via Infotrieve]
23. Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol. 2001; 280: H2313–H2320.
24. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation. 1997; 96: 1580–1585.
25. Chatterjee S, Stewart AS, Bish LT, Jayasankar V, Kim EM, Pirolli T, Burdick J, Woo YJ, Gardner TJ, Sweeney HL. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation. 2002; 106: 212–217.
26. Cross HR, Lu L, Steenbergen C, Philipson KD, Murphy E. Overexpression of the cardiac Na+/Ca2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female, transgenic mice. Circ Res. 1998; 83: 1215–1223.
27. Gabel SA, Cross HR, London RE, Steenbergen C, Murphy E. Decreased intracellular pH is not due to increased H+ extrusion in preconditioned rat hearts. Am J Physiol. 1997; 273: H2257–H2262.[Medline] [Order article via Infotrieve]
28. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Constantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999; 397: 441–446.[CrossRef][Medline] [Order article via Infotrieve]
29. Matsuyama S, Llopi J, Deveraux Q, Tsien R, Reed J. Changes in intramitochondrial and cytosolic pH: Early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000; 2: 318–325.[CrossRef][Medline] [Order article via Infotrieve]
30. Steenbergen C, Perlman ME, London RE, Murphy E. Mechanism of preconditioning. Ionic alterations: ionic alterations. Circ Res. 1993; 72: 112–125.
31. Griffiths EJ. Reversal of mitochondrial Na/Ca exchange during metabolic inhibition in rat cardiomyocytes. FEBS Lett. 1999; 453: 400–404.[CrossRef][Medline] [Order article via Infotrieve]
32. Vander Heiden MG, Chandel NS, Li XX, Schumacker PT, Colombini M, Thompson CB. Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival. Proc Natl Acad Sci U S A. 2000; 97: 4666–4671.
33. LaNoue KF, Watts JA, Koch CD. Adenine nucleotide transport during cardiac ischemia. Am J Physiol. 1981; 241: H663–H671.[Medline] [Order article via Infotrieve]
34. Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. Hypoxia and acidosis activate cardiac myocyte cell death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A. 2002; 99: 12825–12830.
This article has been cited by other articles:
 |
|
 |
|
  K. Ito, H. Akazawa, M. Tamagawa, K. Furukawa, W. Ogawa, N. Yasuda, Y. Kudo, C.-h. Liao, R. Yamamoto, T. Sato, et al. PDK1 coordinates survival pathways and {beta}-adrenergic response in the heart PNAS, May 26, 2009; 106(21): 8689 - 8694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, L. Ebermann, A. Sterner-Kock, S. Wika, H.-P. Schultheiss, A. Dorner, and T. Walther Myocardial overexpression of adenine nucleotide translocase 1 ameliorates diabetic cardiomyopathy in mice Exp Physiol, February 1, 2009; 94(2): 220 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Gustafsson and R. A. Gottlieb Autophagy in Ischemic Heart Disease Circ. Res., January 30, 2009; 104(2): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. K. Mohan, M. Khan, S. Wisel, K. Selvendiran, A. Sridhar, C. A. Carnes, B. Bognar, T. Kalai, K. Hideg, and P. Kuppusamy Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H140 - H151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhai and J. Sadoshima Overcoming an Energy Crisis?: An Adaptive Role of Glycogen Synthase Kinase-3 Inhibition in Ischemia/Reperfusion Circ. Res., October 24, 2008; 103(9): 910 - 913. [Full Text] [PDF]
|
|
|
|
|
|
S. Das, R. Wong, N. Rajapakse, E. Murphy, and C. Steenbergen Glycogen Synthase Kinase 3 Inhibition Slows Mitochondrial Adenine Nucleotide Transport and Regulates Voltage-Dependent Anion Channel Phosphorylation Circ. Res., October 24, 2008; 103(9): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Jin, K. J. Kim, Y. M. Kim, Y. M. Ha, H. J. Kim, U. J. Yun, K. H. Bae, Y. S. Kim, S. S. Kang, H. G. Seo, et al. Anti-Apoptotic Effect of Magnolol in Myocardial Ischemia and Reperfusion Injury Requires Extracellular Signal-Regulated Kinase1/2 Pathways in Rat In Vivo Experimental Biology and Medicine, October 1, 2008; 233(10): 1280 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Champattanachai, R. B. Marchase, and J. C. Chatham Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2 Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1509 - C1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Murphy and C. Steenbergen Ion Transport and Energetics During Cell Death and Protection Physiology, April 1, 2008; 23(2): 115 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Murphy and C. Steenbergen Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury Physiol Rev, April 1, 2008; 88(2): 581 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sanchis, M. Llovera, M. Ballester, and J. X. Comella An alternative view of apoptosis in heart development and disease Cardiovasc Res, February 1, 2008; 77(3): 448 - 451. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Gustafsson and R. A. Gottlieb Heart mitochondria: gates of life and death Cardiovasc Res, January 15, 2008; 77(2): 334 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Liem, H. M. Honda, J. Zhang, D. Woo, and P. Ping Past and present course of cardioprotection against ischemia- reperfusion injury J Appl Physiol, December 1, 2007; 103(6): 2129 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bouwman, R. J. P. Musters, B. J. van Beek-Harmsen, J. J. de Lange, R. R. Lamberts, S. A. Loer, and C. Boer Sevoflurane-induced cardioprotection depends on PKC-{alpha} activation via production of reactive oxygen species Br. J. Anaesth., November 1, 2007; 99(5): 639 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F Rezende, L. F Stoppiglia, K. L A Souza, A. Negro, F. Langone, and A. C Boschero Ciliary neurotrophic factor promotes survival of neonatal rat islets via the BCL-2 anti-apoptotic pathway J. Endocrinol., October 1, 2007; 195(1): 157 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Endo, M. Sano, J. Fujita, K. Hayashida, S. Yuasa, N. Aoyama, Y. Takehara, O. Kato, S. Makino, S. Ogawa, et al. Bone Marrow-Derived Cells Are Involved in the Pathogenesis of Cardiac Hypertrophy in Response to Pressure Overload Circulation, September 4, 2007; 116(10): 1176 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, N. Ma, L.-L. Ong, C. Nesselmann, C. Klopsch, Y. Ladilov, D. Furlani, C. Piechaczek, J. M. Moebius, K. Lutzow, et al. Bcl-2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function Stem Cells, August 1, 2007; 25(8): 2118 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Schwartz, M. K. Manion, C. B. Emerson, J. S. Fry, C. M. Schulz, I. R. Sweet, and D. M. Hockenbery 2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition Mol. Cancer Ther., July 1, 2007; 6(7): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. G. Katakam, J. E. Jordan, J. A. Snipes, C. D. Tulbert, A. W. Miller, and D. W. Busija Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R920 - R926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Walther, C. Tschope, A. Sterner-Kock, D. Westermann, S. Heringer-Walther, A. Riad, A. Nikolic, Y. Wang, L. Ebermann, W.-E. Siems, et al. Accelerated Mitochondrial Adenosine Diphosphate/Adenosine Triphosphate Transport Improves Hypertension-Induced Heart Disease Circulation, January 23, 2007; 115(3): 333 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Gustafsson and R. A. Gottlieb Bcl-2 family members and apoptosis, taken to heart Am J Physiol Cell Physiol, January 1, 2007; 292(1): C45 - C51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hamacher-Brady, N. R. Brady, and R. A. Gottlieb Enhancing Macroautophagy Protects against Ischemia/Reperfusion Injury in Cardiac Myocytes J. Biol. Chem., October 6, 2006; 281(40): 29776 - 29787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Toth, J. R. Jeffers, P. Nickson, J.-Y. Min, J. P. Morgan, G. P. Zambetti, and P. Erhardt Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H52 - H60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Schneider Cyclophilin D: Knocking On Death's Door Sci. Signal., June 7, 2005; 2005(287): pe26 - pe26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Murriel, E. Churchill, K. Inagaki, L. I. Szweda, and D. Mochly-Rosen Protein Kinase C{delta} Activation Induces Apoptosis in Response to Cardiac Ischemia and Reperfusion Damage: A MECHANISM INVOLVING BAD AND THE MITOCHONDRIA J. Biol. Chem., November 12, 2004; 279(46): 47985 - 47991. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||